Program 1: Cancer Genes and Pathways

在新重组的癌症基因和通路(CGP)计划中，研究重点是 具有生物学意义的基因改变和分子途径是癌症发生和发展的基础 免疫监视。这个基础科学项目的主要目标是更好地理解基础知识 肿瘤发生机制和癌症免疫学，从而定义新的分子实体 被用作疾病生物标记物和/或创新的抗癌疗法。这是通过三个步骤完成的 重叠的研究主题集中在1)基因组组织、调控和癌症基因表达，2) 细胞增殖、存活和转化；3)肿瘤免疫监测。关键科学 在上一次资助期间取得的成就包括在理解DNA损伤机制方面的进展 修复和复制，鉴定和表征新的促肿瘤基因改变和 癌症基因网络，癌症创新动物模型的发展，以及通路的确定 控制B和T淋巴细胞的存活和激活。CGP会员包括54名正式会员和6名准会员 成员跨越3个学院的16个系(10个基础科学，6个临床)。年度CGP总资金 上一预算年度同行评议研究的费用为1036万美元(NCI资助2.00美元)，199万美元用于 未经同行评审的研究项目。CGP成员具有高度的协作性，曾撰写或共同撰写 在过去4年中发表了353篇与癌症相关的同行评议出版物，其中17%(n=59)是方案内的，22%是 (n=77)方案间，32%(n=113)机构间。49篇稿件以极高的影响力亮相 日记帐(影响系数&gt；10)。富有成效的方案内/方案间和多机构团体正在发挥领导作用 成熟B系肿瘤(骨髓瘤和非霍奇金淋巴瘤)和神经内分泌肿瘤的研究进展 研究，并对其他人类恶性肿瘤做出重大贡献，包括白血病，乳腺癌， 前列腺癌、黑色素瘤、胰腺癌和肝癌。

Research in the newly restructured Cancer Genes and Pathways (CGP) program focuses on the study of biologically significant genetic alterations and molecular pathways that underlie cancer development and immune surveillance. The primary goal of this basic science program is to better understand fundamental mechanisms of tumorigenesis and cancer immunology, thereby defining new molecular entities that can be exploited as disease biomarkers and/or innovative anti-cancer therapies. This is accomplished through three overlapping research themes centered on 1) genome organization, regulation and cancer gene expression, 2) cellular proliferation, survival and transformation, and 3) tumor immunosurveillance. Key scientific achievements over the prior funding period include advances in understanding mechanisms of damaged DNA repair and replication, identification and characterization of novel tumor-promoting genetic alterations and cancer gene networks, development of innovative animal models of cancer, and determination of pathways controlling B and T lymphocyte survival and activation. CGP membership includes 54 full and 6 associate members spanning 16 departments (10 basic science, 6 clinical) across 3 colleges. Annual CGP total funding for peer-reviewed research in the last budget year was $10.36 million ($2.00 NCI funding) and $1.99 million for non-peer-reviewed research projects. CGP members are highly collaborative having authored or co-authored 353 cancer-related peer-reviewed publications in the past 4 years, with 17% (n=59) intra-programmatic, 22% (n=77) inter-programmatic, and 32% (n=113) inter-institutional. 49 manuscripts appeared in high impact journals (Impact Factor >10). Productive intra-/inter-programmatic and multi-institutional groups are leading advances in mature B lineage tumors (myeloma and non-Hodgkin's lymphomas) and neuroendocrine tumor research, and making major contributions to other human malignancies including leukemias, breast cancer, prostate cancer, melanoma, pancreatic adenocarcinoma and liver cancers.